Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience

#891

Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.

Aim(s): We evaluate retrospectively the efficacy, safety, and tolerability of the sequences of these two different SSA in WDNET observed in our Institute between 1999 and 2013.

Materials and methods: Patients (pt) affected by WD NET were given Oc 30 mg/month or La 120 mg/month by intramuscular injection as first line treatment. At disease progression, pts were given a second line treatment with the other SSA. For each line of treatment, efficacy was evaluated by response rate according to RECIST criteria and in terms of time to tumor progression (TTP). Safety and tolerability were evaluated by assessing the onset of adverse events and treatment feasibility.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: octreotide, lanreotide,

To read the full abstract, please log into your ENETS Member account.